Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,352.96 -1.07 (-0.02%) Dow
38,886.17 +78.84 (+0.20%) Nasdaq
17,173.12 -14.78 (-0.09%) Bitcoin USD
70,801.78 -254.24 (-0.36%) CMC Crypto 200
1,510.59 -14.21 (-0.93%)
PeptiDream Inc. (PPTDF)
- Business Wire
NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma
KAWASAKI, Japan, June 04, 2024--National Cancer Center and PeptiDream Inc.:
- Business Wire
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
KAWASAKI, Japan, April 30, 2024--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG ("hereinafter Novartis") (NYSE: NVS). Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS®") technology to identify and optimize novel macrocyclic pepti
- Business Wire
PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates
KAWASAKI, Japan, September 20, 2023--Combining the PeptiDream's expertise in the field of peptide-RI conjugates, with Genentech's powerful development and commercialization capabilities.
